Genetics of Alzheimer's disease. A rapidly evolving field.

Genetic factors have a variable impact on Alzheimer's Disease (AD), ranging from familial forms that are transmitted in an autosomal dominant fashion to sporadic AD, where a polygenic component is present. Most genes conferring susceptibility to AD are related to amyloid-beta deposition (APP; PS1; PS2; APOE; Cystatin-C; ubiquilin-1), oxidative stress (NOS2; NOS3) and inflammatory response (IL-1 alpha; IL-1 beta; IL-6; TNF-alpha). Genome-wide analyses, transcriptomics and proteomics approaches have pointed also to proapoptotic genes as increasing AD liability. Depression and psychotic symptoms that occur in a large proportion of AD patients have been associated with monoamine genes coding for metabolic enzymes (COMT), transporters (5-HTTLPR) and receptors (DRD1; DRD3). Genetic testing may be useful to confirm the diagnosis of AD in individuals with clinical signs of dementia, while it is generally not recommended as a predictive testing for AD in asymptomatic individuals. Drugs currently in use to treat AD are effective in only 20% of patients; their therapeutic effect is predominantly under genetic control (CYP26 gene; APOE). Environmental factors have been shown to moderate the effects of genes on psychiatric disorders such as depression, schizophrenia and ADHD. The study of gene-environment interactions in AD, that are still poorly understood, is essential to predict disease-risk in asymptomatic individuals. Genomics will provide a dynamic picture of biological processes in AD and new targets for the forthcoming anti-AD drugs.

[1]  L. Murray,et al.  Beta amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[2]  O. Gureje,et al.  Association of apolipoprotein E genotype and Alzheimer disease in African Americans. , 2006, Archives of neurology.

[3]  A. Chan,et al.  Apolipoprotein epsilon-4 allele and the two-year progression of cognitive function in Chinese subjects with late-onset Alzheimer's disease , 2006, American journal of Alzheimer's disease and other dementias.

[4]  L. Feuk,et al.  Mutation screening of a haplotype block around the insulin degrading enzyme gene and association with Alzheimer's disease , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[5]  Dayu Lin,et al.  Alpha-2 macroglobulin I1000V polymorphism in Chinese sporadic Alzheimer's disease and Parkinson's disease , 2002, Neuroscience Letters.

[6]  J. Yesavage,et al.  α2 Macroglobulin and the risk of Alzheimer’s disease , 2000, Neurology.

[7]  A. Kurz,et al.  Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease , 1996, Neurology.

[8]  G. Alexander,et al.  Correlations between apolipoprotein E ε4 gene dose and brain-imaging measurements of regional hypometabolism , 2005 .

[9]  S. Poduslo,et al.  Lack of association of the two polymorphisms in alpha-2 macroglobulin with Alzheimer disease. , 2002, American journal of medical genetics.

[10]  C. Morris,et al.  Lack of association of the α2-macroglobulin locus on chromosome 12 in AD , 2000, Neurology.

[11]  M. Owen,et al.  A full genome scan for late onset Alzheimer's disease , 1999 .

[12]  R. Nitsch,et al.  Association of late-onset Alzheimer disease with a genotype of PLAU, the gene encoding urokinase-type plasminogen activator on chromosome 10q22.2 , 2003, Neurogenetics.

[13]  Henrik Zetterberg,et al.  APOE ε4 allele is associated with reduced cerebrospinal fluid levels of Aβ42 , 2004, Neurology.

[14]  Jeffrey L. Cummings,et al.  The spectrum of behavioral changes in Alzheimer's disease , 1996, Neurology.

[15]  A. M. Saunders,et al.  Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease , 1994, Nature Genetics.

[16]  Jan-Gowth Chang,et al.  The association of beta-site APP cleaving enzyme (BACE) C786G polymorphism with Alzheimer’s disease , 2003, Brain Research.

[17]  E. Masliah,et al.  A polymorphism of the interleukin-1 beta gene at position +3953 influences progression and neuro-pathological hallmarks of Alzheimer’s disease , 2004, Neurobiology of Aging.

[18]  F. Panza,et al.  Candidate genes for late-onset Alzheimer's disease: Focus on chromosome 12 , 2006, Mechanisms of Ageing and Development.

[19]  Giovanni B. Frisoni,et al.  Consensus report of the working group on: 'Molecular and biochemical markers of Alzheimer's disease' , 1998 .

[20]  A. Kurz,et al.  Lack of association between a single nucleotide polymorphism within the choline acetyltransferase gene and patients with Alzheimer's disease , 2003, Neuroscience Letters.

[21]  C. D. de Jager,et al.  APOE alleles predict the rate of cognitive decline in Alzheimer disease , 2005, Neurology.

[22]  A. Quattrone,et al.  Genetic association of &agr;2-macroglobulin polymorphisms with AD in southern Italy , 2002, Neurology.

[23]  S. Hirai,et al.  The levels of cerebrospinal fluid Aβ40 and Aβ42(43) are regulated age-dependently , 2001, Neurobiology of Aging.

[24]  R. Mrak,et al.  Interleukin-1, neuroinflammation, and Alzheimer’s disease , 2001, Neurobiology of Aging.

[25]  S. Duan,et al.  Insulin-degrading enzyme and Alzheimer disease , 2004, Neurology.

[26]  K. Beyreuther,et al.  Alpha 2‐macroglobulin synthesis in interleukin‐6‐stimulated human neuronal (SH‐SY5Y neuroblastoma) cells Potential significance for the processing of Alzheimer β‐amyloid precursor protein , 1991 .

[27]  H. Wiebusch,et al.  Roles for lipoprotein lipase in Alzheimer's disease: An association study , 2000, Microscopy research and technique.

[28]  E. I. Rogaev,et al.  EEG alterations in non-demented individuals related to apolipoprotein E genotype and to risk of Alzheimer disease , 2008, Neurobiology of Aging.

[29]  B. Borroni,et al.  Haplotypes in cathechol-O-methyltransferase gene confer increased risk for psychosis in Alzheimer disease , 2007, Neurobiology of Aging.

[30]  R. Basha,et al.  The Fetal Basis of Amyloidogenesis: Exposure to Lead and Latent Overexpression of Amyloid Precursor Protein and β-Amyloid in the Aging Brain , 2005, The Journal of Neuroscience.

[31]  H. Ulmer,et al.  Amyloid beta 1-42 and tau in cerebrospinal fluid after severe traumatic brain injury , 2003, Neurology.

[32]  J. Growdon,et al.  Rate of progression of Alzheimer's disease is associated with genetic risk. , 1995, Archives of neurology.

[33]  W. Maier,et al.  Polymorphism in the BACE gene influences the risk for Alzheimer's disease , 2003, Neuroreport.

[34]  D. Schaid,et al.  Heritability of plasma amyloid β in typical late‐onset Alzheimer’s disease pedigrees , 2001 .

[35]  Yaakov Stern,et al.  Genetic susceptibility and head injury as risk factors for Alzheimer's disease among community‐dwelling elderly persons and their first‐degree relatives , 1993, Annals of neurology.

[36]  B. Strooper,et al.  α2-macroglobulin expression in neuritic-type plaques in patients with Alzheimer's disease , 1993, Neurobiology of Aging.

[37]  A. Quattrone,et al.  Increased risk for Alzheimer disease with the interaction of MPO and A2M polymorphisms. , 2004, Archives of neurology.

[38]  A D Roses,et al.  Utility of the apolipoprotein E genotype in the diagnosis of Alzheimer's disease. Alzheimer's Disease Centers Consortium on Apolipoprotein E and Alzheimer's Disease. , 1998, The New England journal of medicine.

[39]  J. Gilbert,et al.  Lack of association between UBQLN1 and Alzheimer disease , 2006, American Journal of Medical Genetics Part B: Neuropsychiatric Genetics.

[40]  L. Harrell,et al.  Investigation of association of 13 polymorphisms in eight genes in southeastern African American Alzheimer disease patients as compared to age-matched controls. , 2001, American journal of medical genetics.

[41]  Min Xu,et al.  γ-Secretase: characterization and implication for Alzheimer disease therapy , 2002, Neurobiology of Aging.

[42]  F. Rodríguez‐Artalejo,et al.  Alzheimer's risk associated with human apolipoprotein E, alpha-2 macroglobulin and lipoprotein receptor related protein polymorphisms: absence of genetic interactions, and modulation by gender , 2000, Neuroscience Letters.

[43]  C. Eckman,et al.  Aβ-degrading enzymes: modulators of Alzheimer's disease pathogenesis and targets for therapeutic intervention , 2005 .

[44]  M. Owen,et al.  Ubiquilin 1 polymorphisms are not associated with late‐onset Alzheimer's disease , 2006, Annals of neurology.

[45]  J. C. Torre.  Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics , 2004, The Lancet Neurology.

[46]  P. Jeffrey,et al.  Oral administration of a potent and selective non‐peptidic BACE‐1 inhibitor decreases β‐cleavage of amyloid precursor protein and amyloid‐β production in vivo , 2007 .

[47]  W. Oertel,et al.  Association of an interleukin 1α polymorphism with Alzheimer’s disease , 2000, Neurology.

[48]  J. C. Torre,et al.  Alzheimer Disease as a Vascular Disorder: Nosological Evidence , 2002 .

[49]  R. Martins,et al.  A functional polymorphism within plasminogen activator urokinase (PLAU) is associated with Alzheimer's disease. , 2006, Human molecular genetics.

[50]  G. Perry,et al.  Identification of Ubiquilin, a Novel Presenilin Interactor That Increases Presenilin Protein Accumulation , 2000, The Journal of cell biology.

[51]  Matthew P. Frosch,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[52]  M. Owen,et al.  α-T-catenin is expressed in human brain and interacts with the Wnt signaling pathway but is not responsible for linkage to chromosome 10 in Alzheimer’s disease , 2007, NeuroMolecular Medicine.

[53]  N. Perrimon,et al.  γ‐Secretase/presenilin inhibitors for Alzheimer's disease phenocopy Notch mutations in Drosophila , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[54]  J. Poirier.  Apolipoprotein E in animal models of CNS injury and in alzheimer's disease , 1994, Trends in Neurosciences.

[55]  J. Haines,et al.  Revealing the role of glutathione S-transferase omega in age-at-onset of Alzheimer and Parkinson diseases , 2006, Neurobiology of Aging.

[56]  D. Davis,et al.  Genotypes and haplotypes in the IL-1 gene cluster: analysis of two genetically and diagnostically distinct groups of Alzheimer patients , 2005, Neurobiology of Aging.

[57]  J. Haines,et al.  Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12. , 1997, JAMA.

[58]  S Rabe-Hesketh,et al.  Head injury as a risk factor for Alzheimer’s disease: the evidence 10 years on; a partial replication , 2003, Journal of neurology, neurosurgery, and psychiatry.

[59]  I. Gottesman,et al.  The endophenotype concept in psychiatry: etymology and strategic intentions. , 2003, The American journal of psychiatry.

[60]  J. Chang,et al.  No association of alpha-2 macroglobulin gene five-nucleotide deletion with AD in Taiwan Chinese , 1999, Neurology.

[61]  M. Owen,et al.  A single nucleotide polymorphism in CHAT influences response to acetylcholinesterase inhibitors in Alzheimer's disease , 2006, Pharmacogenetics & Genomics.

[62]  R. Petersen,et al.  Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Aβ42 levels and risk for Alzheimer disease , 2004, Human mutation.

[63]  Jan-Gowth Chang,et al.  Genetic risk factors of sporadic Alzheimer’s disease among Chinese in Taiwan , 2000, Journal of the Neurological Sciences.

[64]  F. Tchantchou,et al.  Dietary supplementation with apple juice concentrate alleviates the compensatory increase in glutathione synthase transcription and activity that accompanies dietary- and genetically-induced oxidative stress. , 2004, The Journal of Nutrition, Health & Aging.

[65]  D. Lahiri.  Where the actions of environment (nutrition), gene and protein meet: beneficial role of fruit and vegetable juices in potentially delaying the onset of Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.

[66]  M. Owen,et al.  Variation in the urokinase‐plasminogen activator gene does not explain the chromosome 10 linkage signal for late onset AD , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[67]  H. Arai,et al.  No genetic association between alpha-2 macroglobulin I1000V polymorphism and Japanese sporadic Alzheimer's disease , 2000, Neuroscience Letters.

[68]  Ze Yang,et al.  Neither the tumor necrosis factor alpha-308 A/G polymorphism nor the alpha2-macroglobulin polymorphism was associated with late-onset Alzheimer's disease in the Chinese population. , 2004, Yi chuan xue bao = Acta genetica Sinica.

[69]  D. Na,et al.  Alpha-1 antichymotrypsin and alpha-2 macroglobulin gene polymorphisms are not associated with Korean late-onset Alzheimer's disease , 2001, Neuroscience Letters.

[70]  N. Kato,et al.  Alzheimer's disease and 5-HTTLPR polymorphism of the serotonin transporter gene: no evidence for an association. , 2000, American journal of medical genetics.

[71]  F. Jessen,et al.  Gene‐gene interaction between interleukin‐6 and α2‐macroglobulin influences the risk for Alzheimer's disease , 2000 .

[72]  C. Ballard,et al.  Neuroleptic drugs in dementia: benefits and harm , 2006, Nature Reviews Neuroscience.

[73]  W. Tsai,et al.  Relative risk of Alzheimer disease and age-at-onset distributions, based on APOE genotypes among elderly African Americans, Caucasians, and Hispanics in New York City. , 1996, American journal of human genetics.

[74]  L. Cupples,et al.  Genetic association between endothelial nitric oxide synthase and Alzheimer disease , 2006, Clinical genetics.

[75]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[76]  L. Thompson,et al.  Progress in the discovery of BACE inhibitors. , 2005, Current pharmaceutical design.

[77]  R. Duara,et al.  No association between the low density lipoprotein receptor-related protein (LRP) gene and late-onset Alzheimer's disease in a community-based sample , 1997, Neuroscience Letters.

[78]  Lin He,et al.  Association Study of the A2M and LRP1 Genes with Alzheimer Disease in the Han Chinese , 2005, Biological Psychiatry.

[79]  H. Manji,et al.  Endophenotypes in bipolar disorder. , 2002, American journal of medical genetics.

[80]  A. Hofman,et al.  Head trauma and the risk of Alzheimer's disease. , 1992, American journal of epidemiology.

[81]  N. Relkin,et al.  The National Institute on Aging/Alzheimer's Association Recommendations on the Application of Apolipoprotein E Genotyping to Alzheimer's Disease a , 1996, Annals of the New York Academy of Sciences.

[82]  Kyungsook Ahn,et al.  ApoE-ε 4-dependent association of the choline acetyltransferase gene polymorphisms (2384G>A and 1882G>A) with Alzheimer's disease , 2006 .

[83]  K. Blennow,et al.  No association between the α2-macroglobulin (A2M) deletion and Alzheimer's disease, and no change in A2M mRNA, protein, or protein expression , 2000, Journal of Neural Transmission.

[84]  S. Sorbi,et al.  The urokinase-plasminogen activator (PLAU) gene is not associated with late onset Alzheimer’s disease , 2005, Neurogenetics.

[85]  B. Pollock,et al.  The 5-HTTPR*S/*L polymorphism and aggressive behavior in Alzheimer disease. , 2001, Archives of neurology.

[86]  N. Bresolin,et al.  Influence of the Glu298Asp polymorphism of NOS3 on age at onset and homocysteine levels in AD patients , 2005, Neurobiology of Aging.

[87]  R. Heun,et al.  Identification of a single nucleotide polymorphism in the choline acetyltransferase gene associated with Alzheimer's disease , 2002, Neuroscience Letters.

[88]  C. Franceschi,et al.  Neuroinflammation and the genetics of Alzheimer’s disease: The search for a pro-inflammatory phenotype , 2001, Aging.

[89]  E. Rogaev,et al.  Alpha-2 macroglobulin gene in early- and late-onset Alzheimer disease , 1999, Neuroscience Letters.

[90]  R. Katzman.,et al.  Apolipoprotein-epsilon4 and head trauma: Synergistic or additive risks? , 1996, Neurology.

[91]  G. Breen,et al.  Association between Alzheimer's disease and the NOS3 gene , 1999, Annals of neurology.

[92]  R. Cadoret,et al.  Associations of the serotonin transporter promoter polymorphism with aggressivity, attention deficit, and conduct disorder in an adoptee population. , 2003, Comprehensive psychiatry.

[93]  A. Singleton,et al.  Nitric oxide synthase gene polymorphisms in Alzheimer's disease and dementia with Lewy bodies , 2001, Neuroscience Letters.

[94]  D. Pham,et al.  Vitamin E Supplementation in Alzheimer's Disease, Parkinson's Disease, Tardive Dyskinesia, and Cataract: Part 2 , 2005, The Annals of pharmacotherapy.

[95]  K. Blennow,et al.  Genetic variation in CTNNA3 encoding alpha-3 catenin and Alzheimer's disease , 2004, Neuroscience Letters.

[96]  K. Davis,et al.  Lack of Association between the Levels of the Low‐Density Lipoprotein Receptor‐Related Protein (LRP) and Either Alzheimer Dementia or LRP Exon 3 Genotype , 2003, Journal of neuropathology and experimental neurology.

[97]  B. de Strooper,et al.  Presenilin 1 Controls γ-Secretase Processing of Amyloid Precursor Protein in Pre-Golgi Compartments of Hippocampal Neurons , 1999, The Journal of cell biology.

[98]  A. Caspi,et al.  Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT Gene , 2003, Science.

[99]  O. Lopez,et al.  Dopamine receptor genetic variation, psychosis, and aggression in Alzheimer disease. , 1998, Archives of neurology.

[100]  M G McInnis,et al.  Evidence for genetic linkage of Alzheimer's disease to chromosome 10q. , 2000, Science.

[101]  M. Macavoy,et al.  Apolipoprotein E ε4 Allele Is Unrelated to Cognitive or Functional Decline in Alzheimer’s Disease: Retrospective and Prospective Analysis , 2006, Dementia and Geriatric Cognitive Disorders.

[102]  Zhenxin Zhang,et al.  Association of α2-macroglobulin polymorphisms and Alzheimer disease in Mainland Han Chinese , 2004, Journal of the Neurological Sciences.

[103]  D. Graham,et al.  Apolipoprotein E ε4 allele is associated with deposition of amyloid β-protein following head injury , 1995, Nature Medicine.

[104]  W. Tsai,et al.  Effect of Age, Ethnicity, and Head Injury on the Association between APOE Genotypes and Alzheimer's Disease , 1996, Annals of the New York Academy of Sciences.

[105]  Taylor J. Maxwell,et al.  Association studies between risk for late‐onset Alzheimer's disease and variants in insulin degrading enzyme , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[106]  F. Jessen,et al.  Identical distribution of the alpha 2-macroglobulin pentanucleotide deletion in subjects with Alzheimer disease and controls in a German population. , 2000, American journal of medical genetics.

[107]  D. Jeste,et al.  Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. , 2005, The American journal of psychiatry.

[108]  K. Blennow,et al.  Cerebrospinal Fluid Beta-Amyloid 42 Is Reduced before the Onset of Sporadic Dementia: A Population-Based Study in 85-Year-Olds , 2003, Dementia and Geriatric Cognitive Disorders.

[109]  Association of early‐onset Alzheimer's disease with an interleukin‐1α gene polymorphism , 2000, Annals of neurology.

[110]  J. Gilbert,et al.  Interaction between the α-T catenin gene (VR22) and APOE in Alzheimer’s disease , 2005, Journal of Medical Genetics.

[111]  D. Y. Lee,et al.  Association of alpha-2-macroglobulin deletion polymorphism with sporadic Alzheimer’s disease in Koreans , 2001, Journal of the Neurological Sciences.

[112]  Eric M Reiman,et al.  Genetics, transcriptomics, and proteomics of Alzheimer's disease. , 2006, The Journal of clinical psychiatry.

[113]  M. Emmerling,et al.  High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. , 1999, Biochemical and biophysical research communications.

[114]  B. Winblad,et al.  Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE , 2007, Neurobiology of Aging.

[115]  Steven D. Edland,et al.  Accelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease , 1998, Neurology.

[116]  Robert A. Copeland,et al.  Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors* , 2000, The Journal of Biological Chemistry.

[117]  S. Tsai,et al.  Lack of association between the interleukin-1alpha gene C(−889)T polymorphism and Alzheimer's disease in a Chinese population , 2003, Neuroscience Letters.

[118]  I. McDowell,et al.  Alzheimer’s disease: Insights from epidemiology , 2001, Aging.

[119]  P. Curatolo,et al.  Lack of association between IDE genetic variability and Down's syndrome , 2005, Neuroscience Letters.

[120]  H. Möller,et al.  Polymorphisms in the α-2 macroglobulin gene in psychogeriatric patients , 2000, Neuroscience Letters.

[121]  B. Hyman,et al.  Lack of association of a polymorphism in the low-density lipoprotein receptor-related protein gene with Alzheimer disease. , 1997, Archives of neurology.

[122]  M. Owen,et al.  Genome screen for loci influencing age at onset and rate of decline in late onset Alzheimer's disease , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[123]  G. Frisoni,et al.  Analysis of Alpha-2-Macroglobulin-2 Allele as a Risk Factor in Alzheimer’s Disease , 2001, Dementia and Geriatric Cognitive Disorders.

[124]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[125]  F. Jessen,et al.  A genetic variation of the inflammatory cytokine interleukin‐6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease , 1999, Annals of neurology.

[126]  D. Middleton,et al.  Association between polymorphism in regulatory region of gene encoding tumour necrosis factor α and risk of Alzheimer's disease and vascular dementia: a case-control study , 2001, The Lancet.

[127]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[128]  Robert C Green,et al.  Association between apolipoprotein E genotype and Alzheimer disease in African American subjects. , 2002, Archives of neurology.

[129]  S. DeKosky,et al.  Lack of association of 5 SNPs in the vicinity of the insulin-degrading enzyme (IDE) gene with late-onset Alzheimer's disease , 2006, Neuroscience Letters.

[130]  R. Go,et al.  The role of TNF and its receptors in Alzheimer’s disease , 2001, Neurobiology of Aging.

[131]  Amy Chan,et al.  Supplementation with apple juice attenuates presenilin-1 overexpression during dietary and genetically-induced oxidative stress. , 2006, Journal of Alzheimer's disease : JAD.

[132]  L. Launer,et al.  Association of interleukin-1 gene polymorphisms with dementia in a community-based sample: The Honolulu-Asia Aging Study , 2006, Neurobiology of Aging.

[133]  B. Tycko,et al.  The deletion polymorphism and Val1000Ile in α-2-macroglobulin and Alzheimer disease in Caribbean Hispanics , 2000, Neuroscience Letters.

[134]  Hilkka Soininen,et al.  Relationship between apoE genotype and CSF β-amyloid (1–42) and tau in patients with probable and definite Alzheimer’s disease , 2000, Neurobiology of Aging.

[135]  A. D. Roses,et al.  Association of apolipoprotein E allele €4 with late-onset familial and sporadic Alzheimer’s disease , 2006 .

[136]  M. Wolfe.  The γ-Secretase Complex: Membrane-Embedded Proteolytic Ensemble , 2006 .

[137]  L. Thal,et al.  Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), and apolipoprotein E receptor, with late-onset Alzheimer's disease , 1997, Neurology.

[138]  M. Luca,et al.  Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment. , 2001, Archives of neurology.

[139]  W. Maier,et al.  Association of the C766T polymorphism of the low‐density lipoprotein receptor‐related protein gene with Alzheimer's disease , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[140]  C. Lyketsos,et al.  Diagnosis and Treatment of Depression in Alzheimer’s Disease , 2003, Dementia and Geriatric Cognitive Disorders.

[141]  L. Hersh,et al.  Insulin-degrading Enzyme Regulates Extracellular Levels of Amyloid β-Protein by Degradation* , 1998, The Journal of Biological Chemistry.

[142]  A. Beekman,et al.  Depression and risk of cognitive decline and Alzheimer's disease , 2000, British Journal of Psychiatry.

[143]  E. Tangalos,et al.  Predictive Value of APOE Genotyping in Incipient Alzheimer's Diseases a , 1996, Annals of the New York Academy of Sciences.

[144]  H. Arai,et al.  Genetic association between alpha-2 macroglobulin and Japanese sporadic Alzheimer's disease , 1999, Neuroscience Letters.

[145]  A. Hofman,et al.  Rates and risk factors for dementia and Alzheimer’s disease , 1999, Neurology.

[146]  M. Kamboh,et al.  Molecular Genetics of Late‐Onset Alzheimer's Disease , 2004, Annals of human genetics.

[147]  P. Lantos,et al.  Alpha-2-macroglobulin intronic polymorphism is not associated with autopsy-confirmed late-onset Alzheimer's disease , 1999, Neuroscience Letters.

[148]  D. Hogan,et al.  Prevalence and types of dementia in the very old , 1994, Neurology.

[149]  S. Corkin,et al.  Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease , 1996, Neurology.

[150]  S. DeKosky,et al.  Genetic association studies between Alzheimer's disease and two polymorphisms in the low density lipoprotein receptor-related protein gene , 1998, Neuroscience Letters.

[151]  G. Rebeck.  Confirmation of the genetic association of interleukin-1A with early onset sporadic Alzheimer's disease , 2000, Neuroscience Letters.

[152]  M. Wolfe.  Secretase as a target for Alzheimer's disease. , 2002, Current topics in medicinal chemistry.

[153]  M. Albert,et al.  Genetic association of an (α2-macroglobulin (Val1000lle) polymorphism and Alzheimer's disease , 1998 .

[154]  L. Tsai,et al.  Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration , 1999, Nature.

[155]  P. May,et al.  The LDL receptor‐related protein (LRP) family: An old family of proteins with new physiological functions , 2007, Annals of medicine.

[156]  Peter M Mathisen,et al.  Gene discovery and validation for neurodegenerative diseases. , 2003, Drug discovery today.

[157]  H. Geerts,et al.  APOE Genotype: No Influence on Galantamine Treatment Efficacy Nor on Rate of Decline in Alzheimer’s Disease , 2001, Dementia and Geriatric Cognitive Disorders.

[158]  C. Haass,et al.  A γ‐secretase inhibitor blocks Notch signaling in vivo and causes a severe neurogenic phenotype in zebrafish , 2002, EMBO reports.

[159]  Robert C Green,et al.  Genetic Risk Assessment for Adult Children of People With Alzheimer’s Disease: The Risk Evaluation and Education for Alzheimer’s Disease (REVEAL) Study , 2005, Journal of geriatric psychiatry and neurology.

[160]  Mitsutoshi Yamamoto,et al.  No association between the insulin degrading enzyme gene and Alzheimer's disease in a Japanese population , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[161]  M. Yamada,et al.  α2-Macroglobulin polymorphism is not associated with AD or AD-type neuropathology in the Japanese , 2000, Neurology.

[162]  R. Kaji,et al.  Influence of polymorphisms in the genes for cytokines and glutathione S-transferase omega on sporadic Alzheimer’s disease , 2004, Neuroscience Letters.

[163]  Claudio Franceschi,et al.  Interleukin-6 gene alleles affect the risk of Alzheimer’s disease and levels of the cytokine in blood and brain , 2003, Neurobiology of Aging.

[164]  F. Jessen,et al.  Association between an interleukin-6 promoter and 3′ flanking region haplotype and reduced Alzheimer's disease risk in a German population , 2000, Neuroscience Letters.

[165]  J. Haines,et al.  Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.

[166]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[167]  O. Combarros,et al.  Gene dose-dependent association of interleukin-1A [-889] allele 2 polymorphism with Alzheimer's disease , 2002, Journal of Neurology.

[168]  H. Manev,et al.  5-Lipoxygenase (5-LOX) promoter polymorphism in patients with early-onset and late-onset Alzheimer's disease. , 2001, The Journal of neuropsychiatry and clinical neurosciences.

[169]  B. Hyman,et al.  Decreased Catalytic Activity of the Insulin-degrading Enzyme in Chromosome 10-Linked Alzheimer Disease Families* , 2007, Journal of Biological Chemistry.

[170]  C. Masters,et al.  Inhibition of γ-Secretase as a Therapeutic Intervention for Alzheimer’s Disease , 2006 .

[171]  S. Antonarakis,et al.  Specific BACE1 genotypes provide additional risk for late‐onset alzheimer disease in APOE ε4 carriers , 2003, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[172]  S. DeKosky,et al.  Three SNPs in the GSTO1, GSTO2 and PRSS11 genes on chromosome 10 are not associated with age-at-onset of Alzheimer's disease , 2005, Neurobiology of Aging.

[173]  M. Owen,et al.  Substantial linkage disequilibrium across the insulin-degrading enzyme locus but no association with late-onset Alzheimer's disease , 2001, Human Genetics.

[174]  M. Bullido,et al.  Apolipoprotein E promoter and α2-Macroglobulin polymorphisms are not genetically associated with Chinese late onset Alzheimer's disease , 1999, Neuroscience Letters.

[175]  H. Baba,et al.  Effect of IL-6 polymorphism on risk of Alzheimer disease: genotype-phenotype association study in Japanese cases. , 2002, American journal of medical genetics.

[176]  J. Haines,et al.  No genetic association between the LRP receptor and sporadic or late-onset familial Alzheimer disease , 1998, Neurogenetics.

[177]  A. Levey,et al.  The Lipoprotein Receptor LR11 Regulates Amyloid β Production and Amyloid Precursor Protein Traffic in Endosomal Compartments , 2006, The Journal of Neuroscience.

[178]  I. Grundke‐Iqbal,et al.  Kinases and phosphatases and tau sites involved in Alzheimer neurofibrillary degeneration , 2007, The European journal of neuroscience.

[179]  K. Blennow,et al.  Sequence variation in the proximity of IDE may impact age at onset of both Parkinson disease and Alzheimer disease , 2004, Neurogenetics.

[180]  V. Álvarez,et al.  Association between an alpha(2) macroglobulin DNA polymorphism and late-onset Alzheimer's disease. , 1999, Biochemical and biophysical research communications.

[181]  A. Serretti,et al.  Pharmacogenetics in the treatment of depression: pharmacodynamic studies , 2005, Pharmacogenetics and genomics.

[182]  Shaharyar M. Khan,et al.  Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer's disease. , 2006, Current Alzheimer research.

[183]  L. Parnetti,et al.  Cerebrospinal fluid biochemical markers in early detection and in differential diagnosis of dementia disorders in routine clinical practice , 2003, Neurological Sciences.

[184]  P. Deyn,et al.  The UBQLN1 polymorphism, UBQ-8i, at 9q22 is not associated with Alzheimer's disease with onset before 70 years , 2006, Neuroscience Letters.

[185]  M. Daly,et al.  Genetic association of Alzheimer's disease with multiple polymorphisms in alpha-2-macroglobulin. , 2003, Human molecular genetics.

[186]  D. Blacker,et al.  Family-based association between Alzheimer's disease and variants in UBQLN1. , 2005, The New England journal of medicine.

[187]  E. Mori,et al.  Accelerated Memory Decline in Alzheimer's Disease With Apolipoprotein ϵ4 Allele , 2003 .

[188]  D. Comas,et al.  Association study between Alzheimer’s disease and genes involved in Aβ biosynthesis, aggregation and degradation: suggestive results with BACE1 , 2003, Journal of Neurology.

[189]  D. Collier,et al.  Psychosis and aggression in Alzheimer's disease: the effect of dopamine receptor gene variation , 2001, Journal of neurology, neurosurgery, and psychiatry.

[190]  T. Golde,et al.  γ-Secretase Cleavage and Nuclear Localization of ErbB-4 Receptor Tyrosine Kinase , 2001, Science.

[191]  M. Ilyas Kamboh,et al.  Genetic variation in the choline acetyltransferase (CHAT) gene may be associated with the risk of Alzheimer's disease , 2006, Neurobiology of Aging.

[192]  M. Petrovecki,et al.  ApoE genotyping and response to galanthamine in Alzheimer's disease--a real life retrospective study. , 2004, Collegium antropologicum.

[193]  B. Devlin,et al.  Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease , 2005, Molecular Psychiatry.

[194]  C. Oddoze,et al.  Association of APOE promoter but not A2M polymorphisms with risk of developing Alzheimer's disease , 2000, Neuroreport.

[195]  G. Vaula,et al.  Association between the interleukin-1α gene and Alzheimer’s disease: a meta-analysis , 2004, Neurobiology of Aging.

[196]  J. Yesavage,et al.  Rate of cognitive decline in AD is accelerated by the interleukin-1α −889 *1 allele , 2001, Neurology.

[197]  Kaj Blennow,et al.  Towards compendia of negative genetic association studies: an example for Alzheimer disease , 2006, Human Genetics.

[198]  C. Morris,et al.  Alpha2-macroglobulin polymorphisms in Alzheimer's disease and dementia with Lewy bodies. , 1999, Neuroreport.

[199]  R. Mayeux,et al.  Predictive utility of apolipoprotein E genotype for Alzheimer disease in outpatients with mild cognitive impairment. , 2005, Archives of neurology.

[200]  R. Green,et al.  Estimating risk curves for first-degree relatives of patients with Alzheimer’s disease: The REVEAL study , 2004, Genetics in Medicine.

[201]  K. Imahori,et al.  Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. , 1997, Journal of biochemistry.

[202]  P. Passmore,et al.  Common polymorphisms in LRP and A2M do not affect genetic risk for Alzheimer disease in Northern Ireland. , 2001, American journal of medical genetics.

[203]  N. Craddock,et al.  Protection against Alzheimer's disease with apoE ∈2 , 1994, The Lancet.

[204]  T. Shea,et al.  Apple juice prevents oxidative stress and impaired cognitive performance caused by genetic and dietary deficiencies in mice. , 2004, The journal of nutrition, health & aging.

[205]  S. DeKosky,et al.  Association of tagSNPs in the urokinase‐plasminogen activator (PLAU) gene with Alzheimer's disease and associated quantitative traits , 2007, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[206]  D. Blacker,et al.  Is α-T catenin (VR22) an Alzheimer’s disease risk gene? , 2006, Journal of Medical Genetics.

[207]  A. Caspi,et al.  Role of Genotype in the Cycle of Violence in Maltreated Children , 2002, Science.

[208]  R. Petersen,et al.  Interleukin-1A polymorphism is not associated with late onset Alzheimer's disease , 2002, Neuroscience Letters.

[209]  F. Jessen,et al.  Polymorphisms in glutathione S-transferase omega-1 and AD, vascular dementia, and stroke , 2004, Neurology.

[210]  D. Campion,et al.  Polymorphisms of insulin degrading enzyme gene are not associated with Alzheimer's disease , 2002, Neuroscience Letters.

[211]  S. Edland.  Insulin-degrading enzyme, apolipoprotein E, and Alzheimer’s disease , 2007, Journal of Molecular Neuroscience.

[212]  Lawrence S. Honig,et al.  Atherosclerosis and AD : Analysis of data from the US national Alzheimer's coordinating center. Author's reply , 2005 .

[213]  P. Bosco,et al.  Association of IL-1 RN*2 allele and methionine synthase 2756 AA genotype with dementia severity of sporadic Alzheimer’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.

[214]  Eden R Martin,et al.  Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. , 2003, Human molecular genetics.

[215]  R. Cacabelos.  Pharmacogenomics and therapeutic prospects in Alzheimer’s disease , 2005, Expert opinion on pharmacotherapy.

[216]  C. DeCarli,et al.  Head injury and the risk of AD in the MIRAGE study , 2000, Neurology.

[217]  A. Roses,et al.  The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. , 1997, JAMA.

[218]  W. Griffin,et al.  Apolipoprotein E distribution among different plaque types in Alzheimer's disease: implications for its role in plaque progression , 1996, Neuropathology and applied neurobiology.

[219]  D. Pollen,et al.  Familial Alzheimer disease: Decreases in CSF Aβ42 levels precede cognitive decline , 2005, Neurology.

[220]  R. Bernabei,et al.  The -174 G/C polymorphism of the interleukin-6 gene promoter is associated with Alzheimer's disease in an Italian population [corrected]. , 2002, Neuroreport.

[221]  Steven M. Horvath,et al.  Alpha-2 macroglobulin is genetically associated with Alzheimer disease , 1998, Nature Genetics.

[222]  H. Arai,et al.  Distribution of apolipoprotein E in senile plaques in brains with Alzheimer's disease: investigation with the confocal laser scan microscope , 1997, Brain Research.

[223]  Association of interleukin‐1 gene polymorphisms with Alzheimer's disease , 2000, Annals of neurology.

[224]  Bradley R. Johnson,et al.  American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition. , 2007, The American journal of psychiatry.

[225]  Z. Janka,et al.  α 2-Macroglobulin exon 24 (Val-1000-Ile) polymorphism is not associated with late-onset sporadic Alzheimer's dementia in the Hungarian population , 2002, Psychiatric genetics.

[226]  Ramón Cacabelos,et al.  Pharmacogenomics in Alzheimer's disease. , 2000, Methods in molecular biology.

[227]  J. Cumming,et al.  Design and development of BACE-1 inhibitors. , 2004, Current opinion in drug discovery & development.

[228]  T. Ogihara,et al.  Low density lipoprotein receptor‐related protein gene polymorphisms and risk for late‐onset Alzheimer's disease in a Japanese population , 2000, Clinical genetics.

[229]  L. Wynne,et al.  Genotype–environment interaction in schizophrenia-spectrum disorder , 2004, British Journal of Psychiatry.

[230]  A. Lustig,et al.  Alterations in immunological and neurological gene expression patterns in Alzheimer's disease tissues. , 2007, Experimental cell research.

[231]  D. Comas,et al.  Joint analysis of candidate genes related to Alzheimer's disease in a Spanish population , 2003, Psychiatric genetics.

[232]  Leonid Tarassishin,et al.  Processing of Notch and amyloid precursor protein by γ-secretase is spatially distinct , 2004 .

[233]  Janice E. Knoefel,et al.  Apolipoprotein E element 4 association with dementia in a population-based study , 1996, Neurology.

[234]  A D Roses,et al.  Apolipoprotein E alleles as risk factors in Alzheimer's disease. , 1996, Annual review of medicine.

[235]  L. Feuk,et al.  Elevated amyloid beta protein (Abeta42) and late onset Alzheimer's disease are associated with single nucleotide polymorphisms in the urokinase-type plasminogen activator gene. , 2005, Human molecular genetics.

[236]  S. DeKosky,et al.  Genetic association of ubiquilin with Alzheimer's disease and related quantitative measures , 2006, Molecular Psychiatry.

[237]  Y. Zhang,et al.  Association between low-density lipoprotein receptor-related protein gene, butyrylcholinesterase gene and Alzheimer' s disease in Chinese. , 2001, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.

[238]  L. Feuk,et al.  Genetic variation in a haplotype block spanning IDE influences Alzheimer disease , 2003, Human mutation.

[239]  S. Sorbi,et al.  α2-Macroglobulin polymorphisms in Italian sporadic and familial Alzheimer's disease , 2001, Neuroscience Letters.

[240]  N. Cairns,et al.  Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[241]  C. Caltagirone,et al.  Glutathione S-Transferase P1 *C Allelic Variant Increases Susceptibility for Late-Onset Alzheimer Disease: Association Study and Relationship with Apolipoprotein E ε4 Allele , 2005 .

[242]  B. Hyman,et al.  Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor protein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[243]  J. Trojanowski,et al.  12/15-lipoxygenase is increased in Alzheimer's disease: possible involvement in brain oxidative stress. , 2004, The American journal of pathology.

[244]  Bosheng Zhang,et al.  Genetic studies of A2M and BACE1 genes in Chinese Han Alzheimer's disease patients , 2005, Neuroreport.

[245]  S. Gauthier,et al.  Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[246]  R. Martins,et al.  TNF polymorphisms in Alzheimer disease and functional implications on CSF beta‐amyloid levels , 2005, Human mutation.

[247]  S. Roberts.  γ-Secretase inhibitors and Alzheimer’s disease , 2002 .

[248]  S. Faraone,et al.  Meta‐analysis of the association between two polymorphisms in the serotonin transporter gene and affective disorders , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[249]  K. Yanagisawa,et al.  Age-Dependent Change in the Levels of Aβ40 and Aβ42 in Cerebrospinal Fluid from Control Subjects, and a Decrease in the Ratio of Aβ42 to Aβ40 Level in Cerebrospinal Fluid from Alzheimer’s Disease Patients , 2000, European Neurology.

[250]  B. Pollock,et al.  The 5-HTTPR Polymorphism Confers Liability to a Combined Phenotype of Psychotic and Aggressive Behavior in Alzheimer Disease , 2001, International Psychogeriatrics.

[251]  Michael C. Neale,et al.  Stressful life events, genetic liability, and onset of an episode of major depression in women. , 1995, The American journal of psychiatry.

[252]  C. Arias,et al.  Differential effects of COX inhibitors against β-amyloid-induced neurotoxicity in human neuroblastoma cells , 2005, Neurochemistry International.

[253]  J. Schwartz,et al.  Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's disease , 2004, Molecular Psychiatry.

[254]  A. Hofman,et al.  Head trauma and risk of dementia and Alzheimer’s disease , 1999, Neurology.

[255]  R. Vassar.  The beta-secretase, BACE: a prime drug target for Alzheimer's disease. , 2001, Journal of molecular neuroscience : MN.

[256]  S. Younkin,et al.  Fine mapping of the alpha-T catenin gene to a quantitative trait locus on chromosome 10 in late-onset Alzheimer's disease pedigrees. , 2003, Human molecular genetics.

[257]  M. Gold,et al.  The alpha-2 macroglobulin gene is not associated with Alzheimer's disease in a case-control sample , 1999, Neuroscience Letters.

[258]  Q. Qu,et al.  Interleukin-1 gene cluster polymorphisms and risk of Alzheimer’s disease in Chinese Han population , 2004, Journal of Neural Transmission.

[259]  N. Zawia,et al.  Environmental Risk Factors and the Developmental Basis for Alzheimer's Disease , 2005, Reviews in the neurosciences.

[260]  P. Liao,et al.  Lack of Association Between Interleukin‐1&agr; Polymorphism and Alzheimer Disease or Vascular Dementia , 2003, Alzheimer disease and associated disorders.

[261]  A. Myers,et al.  Insulin-Degrading Enzyme Haplotypes Affect Insulin Levels but Not Dementia Risk , 2007, Neurodegenerative Diseases.

[262]  Tyrone D. Cannon,et al.  Quantitative neural indicators of liability to schizophrenia: implications for molecular genetic studies. , 2001, American journal of medical genetics.

[263]  David A Bennett,et al.  The apolipoprotein E epsilon 4 allele and decline in different cognitive systems during a 6-year period. , 2002, Archives of neurology.

[264]  J. Poirier,et al.  Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease. , 1998, Journal of neural transmission. Supplementum.

[265]  D. Easton,et al.  Genome-wide linkage disequilibrium mapping of late-onset Alzheimer’s disease in Finland , 2001, Neurology.

[266]  J. Lambert,et al.  Association study of the Ubiquilin gene with Alzheimer's disease , 2006, Neurobiology of Disease.

[267]  S. Gandy,et al.  The role of cerebral amyloid β accumulation in common forms of Alzheimer disease , 2005 .

[268]  O. Combarros,et al.  Candidate Gene Association Studies in Sporadic Alzheimer’s Disease , 2002, Dementia and Geriatric Cognitive Disorders.

[269]  C. Morris,et al.  Rate of progression of cognitive decline in Alzheimer’s disease: effect of butyrylcholinesterase K gene variation , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[270]  C. Holmes,et al.  Association between interleukin 1‐β promoter (−511) polymorphism and depressive symptoms in Alzheimer's disease , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.